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ABSTRACT
The first therapeutic indication, and still currently the most applied of gamma globulin, is the one which
uses its substitutive capacity in patients with antibodies deficiencies. Its immunomodulatory effective-
ness with pro and anti-inflammatory activity holds a second place in their indications, in autoimmune and
inflammatory illnesses. The first gamma globulin to be used in patients with agammaglobulinemia in
the 50’s, were of intramuscular administration, with significant limitations on the volume and the infu-
sion’s amount, as well as being painful . For over 20 years intravenous immunoglobulin (IVIG) has been
widely used in human pathology. The first proteolytic enzyme-treated intravenous immunoglobulins al-
lowed large doses infusions, thereby getting higher levels of IgC circulating in plasma, a subclass profile
similar to the normal population, as well as a much higher average life expectancy. The pharmaceutical
industry efforts brought about new more purified and viral safer immunoglobulins. The Cohn and cold
ethanol methods were quickly supplemented with ulterior procedures that strengthened the viral safety of
these products. The application of molecular techniques to the screening study of plasma donors, as
well as incorporating new viral inactivation procedures during its manufacture, have made of IVIG a safe
product whose consumption has exponentially increased in recent years. IVIG’s high cost, the hypotheti-
cal plasma supply problems and risks associated to its administration made essential the writing of
usage protocols for official agencies, which, besides, hospitals also adopted.
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Introduction
The IVIG restoration therapy in primary immu-
nodeficiencies (PID) achieves replacing the lack of
antibodies in these patients, preventing the occurrence
of infections and long-term complications, especially
1. Servei  d’Inmunología. Hospital Universitari Son Espases. Spain.
digestive and lung related. Most IVIG have its origin
in plasma fractionation derived by Cohn-ethanol’s
method or some of its modifications. These first prod-
ucts presented with aggregated of IgG and anti-com-
plementary activity, which could cause anaphylactic
reactions. Current IVIG have been suitably modified
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to solve these problems. Viral inactivation processes
have been supplemented with adding new treatments
such as using solvent-detergent, nanofiltration or pas-
teurization. From 1982 the WHO has been recom-
mending a 90% monomeric IgC constitution for IVIG
as well as for them to present less than 5% aggre-
gated IgG. IgG must maintain its bacterial toxins and
viruses neutralization capabilities, as well as its op-
sonizing ability mediated by phagocytes. Despite IgG’s
wealth in different IVIG presentations being close to
98% small quantities of IgA can be found, as well as
some coagulation’s cascade proteins. Since discover-
ing in the early 80’s the immunomodulatory properties
of IVIG, its application in autoimmune and inflamma-
tory diseases has greatly increased.
Indications for IVIG therapy
IVIG is currently used in hospitals as a replace-
ment therapy in primary and secondary immunodefi-
ciencies, as well as an immunomodulatory therapy and
/ or anti-inflammatory in different pathologies. Cur-
rently there are seven indications for an IVIG treat-
ment (replacement and immunomodulatory) approved
by the European Medicines Agency (EMEA) (1, 2).
However, its actual field of application is much broader.
In a daily practice is used on more than 50 diseases
not recognized by the EMEA, in which the scientific
evidence of its benefits is highly variable (3, 4, 5, 6, 7,
8, 9, 10). All of the above, the product’s high price, its
production limitation and the risks arising from its use,
have made increasingly necessary drafting indication
strict hospital protocols.
Proposed Protocol of IVIG Indica-
tions and prescription at the Univer-
sity Hospital Son Espases (HUSE)
For the development of this therapeutic guide a
complete review on the use of IVIG published in re-
cent years was conducted. Moreover it was contrasted
with the indications commonly used in our hospital.
Following the last protocol’s pattern performed at Son
Dureta Hospital on the issue (December, 2000), indi-
cations were divided into 1) approved indications: the
one numerically most important, the ones with an old-
est establishment, recommended and accepted by in-
ternational therapeutic guidelines; 2) other approved
indications, with a current rating making them elective
treatments and, finally; 3) technically unapproved in-
dications but supported by controlled clinical trials
which, theoretically, would require following the com-
passionate use procedure. All entries accepted at the
Hospital follow the EMEA recommendations and those
not recognized as off-label, require the compassion-
ate use application. In addition, the Pharmacy and
Therapeutics Hospital Committee must establish the
conditions of use for which the drug can be applied on
patients in which the medication’s advantages and
benefits can be significantly clinically objectified and
with a valued cost. In cases in which the clinical trials
results provide enough evidence, it may be possible to
consider the applications, which allows a rational drugs
use, on those patients who really have shown a sig-
nificant or probable clinical benefit.
Requirements for compassionate
use of IVIG
There are not considered clinical conditions for
IVIG use in the data sheet that require performing a
compassionate use application. At the Hospital an ap-
plication form for compassionate use of drugs can be
found. These forms provide the request to be justified
and for the necessary information to be furnished, lit-
erature (evidence on the efficacy and safety), condi-
tions of use and other relevant data for the compas-
sionate use indication to be made with clinical accu-
racy.
Situations that require the evalua-
tion committee’s authorization
An AD Hoc Evaluation Committee consisting
on specialist Pharmacy Services and Hospital Immu-
nology Department experts will intervene in all cases
in which the benefit of treatment with IVIG is unlikely
(even being its indication approved by the EMEA) but
there may be some special medical condition that ad-
vises its use. The assessment ought to be made on a
case by case basis. The specialist requiring the suit-
ability of the treatment will also participate in the evalu-
ation; the Evaluation Committee may summon an ex-
pert from another specialty as a consultant if it sees
fit.
Application for an IVIG use authorization to the
Evaluation Committee will also be mandatory in
pathologies not included in this document or in those
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where the potential benefit of an IGIV treatment is
not adequately supported by any of the three criteria
mentioned above. These special situations may include
conditions, such as prevention of recurrent genital her-
pes or prevention of recurrent pulmonary infection in
patients with hypogammaglobulinemia and impaired
secondary antibody response to immunosuppressive
therapy in COPD.
Being IVIG a derived product from human
plasma it can, for various reasons, present with short-
ages or scarcity; the Evaluation Committee may
prioritize indications in these situations. This Protocol
shall be updated at least every two years, including
the amendments which have arisen from new indica-
tions as well as removing those that have proven un-
successful. In all cases the practice of Evidence and
Ethics Based Medicine and must always take into
account the patient’s clinical benefit.




- Predominantly antibody deficiencies. Severe Com-
bined immunodeficiencies
- Well defined syndromes with immunodeficiency
and others immunodeficiencies
• Secondary immunodeficiencies
- Antibody deficiencies secondary to LLC. Antibody
deficiency secondary to Mieloma





- Guillain–Barre syndrome. Multifocal motor neu-
ropathy. Chronic inflammatory demyelinating neu-
ropathy. Other immunomediated demyelinating
neropathy (CIDP-like)
- Myastenia gravis. Lambert –Eaton Syndrome. Mul-
tiple sclerosis. Stiff-person disease
• Autoimmunity
- Peripheral or CNS affectation in autoimmune dis-
eases. Dermatomyositis. ANCA positive systemic
vasculitis. Severe infections in out –break autoim-
mune disease
• Pediatrics
- Kawasaki disease. Neonatal sepsis
Immunoglobulins for subcutaneous
use
For several years there has now been another
type of presentation for human gamma globulin with a
via-subcutaneous use (IGSUBCU) (11,12).
This alternative therapy has been put into prac-
tice as a replacement therapy in patients with primary
and secondary antibody immunodeficiencies; little by
little the number of patients receiving it has expanded.
Continuing learning on the infusion’s mechanics is
taught at our Day Care Hospital. Teaching is per-
formed by specialized personnel and every 6 months
the patient must come to the hospital to receive an
infusion so to ensure a successful procedure. Treat-
ment is usually performed at home, which prevents
the patient’s displacement to the hospital. It is particu-
larly suitable for children and adults with a less than
50-60 kilos weight. The infusion is carried out by spe-
cial pumps through special tracts, usually injecting the
abdomen, the thighs, the hips or the arm; more than
one infusion point may be used simultaneously. Treat-
ment should be done on a weekly basis. Experience
has shown that through these subcutaneous gamma
globulins the replacement effect is generally success-
ful and IgG pre-infusion levels are achieved and some-
times even higher ones than those obtained with the
same dose of IVIG provided every 21-28 days. To the
Hospital it represents a lower use of the Day Care
Hospital’s resources. There are, as well as with the
intravenous one, different concentrations of subcuta-
neous gammaglobulin. In the Spanish market 20%
concentration type can be found. They are usually very
well tolerated by patients; however they sometimes
present with after infusion discrete local reactions.
Secondary adverse reactions to
IVIG administration
IVIG infusion is not without side effects. The
most common adverse reactions are closely related to
the infusion’s rate. Most of these reactions are mild
and reversible and occur in about 15-20% of all infu-
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sions. They can’t be foreseen, but they usually appear
at the end of the infusion when speed at its highest;
they can also reveal themselves over 24 hours follow-
ing the infusion. Special care must be taken when these
reactions take place, during the first infusion in newly
diagnosed patients or those chronically infected or
acute infected at the time of infusion. The most effec-
tive measure to take at the onset of these reactions is
to slow down or stopping the infusion whether symp-
toms do not disappear. If patients were to repeat these
reactions on subsequent infusions, the speed ought to
be lowered to the maximum tolerated by the patient; it
can sometimes be premedicated with nonsteroidal anti-
inflammatory drugs or antihistamines. The most com-
mon reactions reported in literature are: fever, chills,
flushing, tachycardia, palpitations and chest pain. To a
lesser extent but also often they may present with high
anxiety, nausea, abdominal pain, dyspnea, arthralgia /
myalgia. Exceptionally hypotension and shock occur.
The etiology of these reactions has been linked to the
formation of antigen-antibody complexes, immu-
noglobulin recognizing the antigens present on the in-
fectious agent may be another possible mechanism of
complement activation or the presence of vasoactive
amines contaminants in the product. Infrequent reac-
tions and having a higher severity are: aseptic menin-
gitis, neutropenia, urticaria and maculopapular rash,
leukocytoclastic vasculitis, thromboembolic events,
which can manifest as deep as in thrombosis vein or
myocardial infarction reach and very rarely with renal
failure. Occasionally these reactions are related to
characteristics of the product, but especially with in-
fusion of high doses of IVIG (13,14).
Our experience at the University Hospital Son
Espases between 1982-2012 showed that from a total
of 30,600 infusions about 20-30% are to provoke fre-
quent mild reactions and less than 1% rare or severe
reactions.
Conclusions
IVIG is an product with few side effects and
an excellent safety standards. In the last years a rapid
expansion in the use of IVIG for an important number
of conditions was appeared The major impact of IVIG
treatment applied to neurology, haematology, immu-
nology, rheumatology and dermatology. Many of the
side effects related to IVIG treatment were mild and
with a easy control in a day care hospital. The limita-
tions for IVIG treatments are the cost, it is necessary
to maintain a good hospital organization for its admin-
istration. The future availability of IVIG product has
been a concern, especially for primary immunodefi-
ciency patients since at this moment there are not al-
ternative therapies for these patients.
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RESUMO
A primeira indicação terapêutica e, ainda hoje, a mais utilizada da gamaglobulina humana é aquela que
usa a sua capacidade de substituição em pacientes com deficiências de anticorpos. Sua capacidade
imunomoduladora, com atividades pro e anti-inflamatória, ocupam segundo lugar dentro de suas indi-
cações, em doenças autoimunes e inflamatórias. As primeiras gamaglobulinas que foram utilizadas
nos anos 50 em pacientes com agamaglobulinemia, tinham aplicação intramuscular, com limitações
significativas relativas à dor, ao volume e a quantidade de infusão. Durante os últimos 20 anos, as
imunoglobulinas intravenosas (IVIG) têm sido amplamente utilizadas em patologias humanas diver-
sas. As primeiras IVIG tratadas por enzimas proteolíticas permitiram a infusão de grandes quantidades,
obtendo assim níveis mais elevados de IgG sérica circulante, com um perfil de subclasses semelhante
ao da população normal e uma vida média muito superior. O esforço da indústria farmacêutica fez com
que aparecessem novas imunoglobulinas mais purificadas e com maior segurança contra infecções
virais. Os métodos de Cohn e cold etanol foram rapidamente complementados com outros procedi-
mentos que reforçavam a segurança antiviral desses produtos. A aplicação de técnicas moleculares
para o estudo de rastreio do plasma dos doadores, bem como a incorporação de novos processos de
inativação viral durante seu processo de fabricação, faz das IVIG um produto seguro cujo consumo tem
aumentado exponencialmente nos últimos anos. O alto custo das IVIG, os hipotéticos problemas de
desabastecimento de plasma e os riscos associados à sua administração tornaram essencial a reda-
ção de protocolos de uso para as agências oficiais que os hospitais também adotaram.
Palavras-chave: Imunoglobulinas. Terapia Biológica. Função Imunológica.
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